(Bloomberg) -- Eli Lilly & Co. surged in pre-market trading as its experimental treatment for Alzheimer’s disease showed promise in a mid-stage clinical trial.
Patients who received donanemab showed significant slowing of decline in a measure of cognition and daily function in patients with early Alzheimer’s disease compared to placebo, Lilly said Monday in a statement. The shares gained 16% in trading before U.S. markets opened.
Companies have been searching for a treatment to target beta-amyloid, an abnormal protein that accumulates in the brains of Alzheimer’s patients that’s believed to be linked to the disease.
Donanemab is an investigational antibody that targets a modified form of beta-amyloid called N3pG, according to the statement. Donanemab slowed the decline of the composite measure by 32% relative to placebo.
Últimas Noticias
Debanhi Escobar: they secured the motel where she was found lifeless in a cistern
Members of the Specialized Prosecutor's Office in Nuevo León secured the Nueva Castilla Motel as part of the investigations into the case
The oldest person in the world died at the age of 119
Kane Tanaka lived in Japan. She was born six months earlier than George Orwell, the same year that the Wright brothers first flew, and Marie Curie became the first woman to win a Nobel Prize
Macabre find in CDMX: they left a body bagged and tied in a taxi
The body was left in the back seats of the car. It was covered with black bags and tied with industrial tape
The eagles of America will face Manchester City in a duel of legends. Here are the details
The top Mexican football champion will play a match with Pep Guardiola's squad in the Lone Star Cup
Why is it good to bring dogs out to know the world when they are puppies
A so-called protection against the spread of diseases threatens the integral development of dogs
